Science:Life Sciences
The biotechnology industry continued to post record numbers, attract significant investment, and won approval for a solid number of new drugs in 2015. Nevertheless, EY in its new Beyond Borders report warns that there’s a deceleration within the industry that points to threats that could undermine the robust growth it has enjoyed. We spoke to Glen Giovannetti, EY Global Biotechnology Leader, about the new report, the need for the industry to innovate pricing models for new drugs, and why as companies seeks to demonstrate the value of a product they will need to consider the unique perspective of each payer.
view more
More Episodes
Making A Social Contract That’s Enforceable
2020-03-12
2020-03-12
Fishing for New Drugs
2020-02-27
2020-02-27
Quantifying Neurodegeneration with Precision
2020-01-30
2020-01-30
Reversing Disease Signals
2020-01-16
2020-01-16
Turning Cold Tumors Hot
2020-01-09
2020-01-09
An Effort to Eradicate Preventable Blindness
2019-12-20
2019-12-20
Seeking Success Where Others Have Failed
2019-12-19
2019-12-19
Improving Health with Better Data
2019-12-05
2019-12-05
Get this podcast on your
phone, FREE
